Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3962590 | 1.00 | FUCA1 (0.50) | FUCA1 | |
| SCHEMBL5870381 | 0.87 | FUCA1 (0.42) | FUCA1 | |
| SCHEMBL15628060 | 0.85 | FUCA1 (0.46) | FUCA1 | |
| SCHEMBL6549494 | 0.83 | FUCA1 (0.50) | FUCA1 | |
| SCHEMBL6870012 | 0.83 | FUCA1 (0.50) | FUCA1 | |
| SCHEMBL6867646 | 0.83 | FUCA1 (0.50) | FUCA1 | |
| SCHEMBL14094624 | 0.82 | — | — | |
| SCHEMBL15107903 | 0.82 | — | — | |
| SCHEMBL13576467 | 0.82 | — | — | |
| SCHEMBL10050297 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023219075-A1 | METHOD FOR MANUFACTURING SUBSTRATE EQUIPPED WITH WEAK ANCHORING ALIGNMENT FILM, AND METHOD FOR MANUFACTURING LIQUID CRYSTAL DISPLAY ELEMENT | 日産化学株式会社 | 2023-11-16 | — | — | WO | disclosed |
| CN-116675618-A | N, N' -bis (aminobenzoyl) cyclohexane diamine for polyimide synthesis and derivatives thereof, preparation method and application thereof | 天津科技大学 | 2023-09-01 | — | — | CN | disclosed |
| US-20140037850-A1 | CORROSION AND WEAR RESISTANT ORGANIC COATINGS | GENERAL ELECTRIC COMPANY (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140037850-A1 | CORROSION AND WEAR RESISTANT ORGANIC COATINGS | GENERAL ELECTRIC COMPANY (US) | 2014-02-06 | — | — | US | disclosed |
| EP-1517911-B1 | TUMOUR-INHIBITING PLATINUM (II) OXALATE COMPLEXES | KEPPLER PROF DR DR BERNHARD K (AT) | 2009-07-29 | — | — | EP | disclosed |
| US-7057059-B2 | Tumor-inhibiting platinum (II) oxalate complexes | FAUSTUS FORSCHUNGS CIE. TRANSLATIONAL CANCER RESEARCH GMBH (DE) | 2006-06-06 | — | — | US | disclosed |
| US-20050143455-A1 | Tumor-inhibiting platinum (II) oxalate complexes | FAUSTUS FORSCHUNGS CIE. TRANSLATIONAL CANCER RESEARCH GMBH | 2005-06-30 | — | — | US | disclosed |
| EP-1517911-A1 | TUMOUR-INHIBITING PLATINUM (II) OXALATE COMPLEXES | Faustus Forschungs Cie. Translational Cancer Research GmbH (DE) | 2005-03-30 | — | — | EP | disclosed |
| WO-2003106469-A1 | TUMOUR-INHIBITING PLATINUM (II) OXALATE COMPLEXES | FAUSTUS FORSCHUNGS CIE. TRANSLATIONAL CANCER RESEARCH GMBH (DE) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143455-A1 | Tumor-inhibiting platinum (II) oxalate complexes | OXGR1, OAT, OXA1L | FUCA1 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.